Description

CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM)[1].—COVID-19-anti-virus–C29H41F2N5—-[1]Jecs E, et al. Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. J Med Chem. 2022, 65(5):4058-4084.–2761009-30-5–497.67—-FC1(F)CCC(N(CCCCN([C@@H]2C3=NC=CC=C3CCC2)C[C@@H]4NCC5=C(C4)N=CC=C5)C)CC1–Inflammation/Immunology–10 mM in DMSO–CXCR;HIV–CXCR4;HIV–Anti-infection;GPCR/G Protein;Immunology/Inflammation–Peptides